Staurosporine analogues - Pharmacological toys or useful antitumour agents?

Critical Reviews in Oncology/Hematology

Volumn 34, Issue 2, 2000, Pages 127-135

  Gescher, Andreas ^a  

^a MRC TOXICOLOGY UNIT   (United Kingdom)

Author keywords

Anticancer activity; Clinical trials; Cyclin dependent kinases; Protein kinase C; Staurosporine analogues

Indexed keywords

7 HYDROXYSTAUROSPORINE; ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE; ISOENZYME; MIDOSTAURIN; PROTEIN KINASE C; STAUROSPORINE DERIVATIVE;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER; CELL CYCLE; CELL PROLIFERATION; CLINICAL TRIAL; DRUG DESIGN; DRUG MECHANISM; HUMAN; NONHUMAN; REVIEW;

EID: 0034013507     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(00)00058-5     Document Type: Article

References (62)

1. Powis G. Anticancer drugs acting against signaling pathways. Curr Opin Oncol. 7:1995;554-559.
2. Omura S., Iwai Y., Hirano A. et al. A new alkaloid AM-2282 of Streptomyces origin: taxonomy, fermentation, isolation and preliminary characterisation. J Antibiot. 30:1977;706-708.
3. Caravatti G., Meyer T., Fredenhagen A. et al. Inhibitory activity and selectivity of staurosporine derivatives towards protein kinase C. Bioorganic Med Chem Lett. 4:1994;399-404.
4. Jaken S. Protein kinase C isozymes and substrates. Curr Opinion Cell Biol. 8:1996;168-173.
5. Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science. 258:1992;607-614.
6. Castagna M., Takai Y., Kaibuchi K. et al. Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. J Biol Chem. 275:1982;7847-7851.
7. Pawson T., Saxton T.M. Signaling networks - do all roads lead to the same genes? Cell. 97:1999;675-678.
8. O'Brian C.A., Vogel V.G., Singletary S.E., Qward N.E. Elevated protein kinase C expression in human breast tumor biopsies relative to normal breast tissue. Cancer Res. 49:1989;3215-3217.
9. Benzil D.L., Finkelstein S.D., Epstein M.H., Finch P.W. Expression pattern of α-protein kinase C in human astrocytomas indicates a role in malignant progression. Cancer Res. 52:1992;2951-2956.
10. Cacace A.M., Nichols Guadagno S., Krauss R.S. et al. The epsilon isoform of protein kinase C is an oncogene when oversupressed in rat fibroblasts. Oncogene. 8:1993;2104-2104.
11. Kopp P., Noelke B., Sauter G. et al. Altered protein kinase C activity in biopsies of human colonic adenomas and carcinomas. Cancer Res. 51:1991;205-210.
12. Fine R.L., Patel J., Chabner B.A. Phorbol esters induce multidrug resistance in human breast cancer cells. Proc Natl Acad Sci USA. 85:1988;582-586.
13. Yu G., Ahmad S., Aquino A. et al. Transformation with protein kinase C-alpha confers increased multi-drug resistance in human breast cancer cells. Cancer Commun. 3:1991;181-188.
14. Ahmad S., Glazer R.I. Expression of the antisense cDNA for protein kinase C-α attenuates resistance in doxorubicin-resistant MCF-7 breast carcinoma cells. Mol Pharmacol. 43:1993;858-862.
15. Budworth J., Gant T.W., Gescher A. Co-ordinate loss of protein kinase C and multidrug resistance gene expression in revertant MCF-7/Adr breast carcinoma cells. Br J Cancer. 75:1997;1330-1335.
16. Germann U.A., Chambers T.C., Ambudkar S.V. et al. Characterization of phosphorylation-defective mutants of human P-glycoprotein expressed in mammalian cells. J Biol Chem. 271:1996;1708-1716.
17. Goodfellow H.R., Sardini A., Ruetz S. et al. Protein kinase C-mediated phosphorylation does not regulate drug transport by the human multidrug resistance P-glycoprotein. J Biol Chem. 271:1996;13668-13674.
18. Nixon JS. The biology of protein kinase C inhibitors, In: Parker PJ and Dekker LV editors, Molecular Biology Intelligence Unit. Protein Kinase C. RG Landes, Austin TX; Springer Verlag, Heidelberg, 205-36.
19. Meyer T., Regenass U., Fabbro D. et al. A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity. Int J Cancer. 43:1989;851-856.
20. Ikegami Y., Yano S., Nakao K. Effects of the new selective kinase C inhibitor 4′-N-benzoyl-staurosporine on cell cycle distribution and growth inhibition in human small cell lung cancer cells. Arzneimittelforschung. 46:1996;201-204.
21. Ikegami K., Yano S., Nakao K. Antitumour effect of CGP41251, a new selective protein kinase C inhibitor, on human non-small cell lung cancer cells. Jpn J Pharmacol. 70:1996;65-72.
22. Begemann M., Kashimawo S.A., Choi J.A. et al. Inhibition of the growth of glioblastomas by CGP 41 251, an inhibitor of protein kinase C, and by a phorbol ester tumor promoter. Clin Cancer Res. 2:1996;1017-1030.
23. Akinaga S., Gomi K., Morimoto M. et al. Antitumour activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models. Cancer Res. 51:1991;4888-4892.
24. Seynaeve C.M., Stetler-Stevenson M., Sebers S. et al. Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells. Cancer Res. 53:1993;2081-2086.
25. Pollack I.F., Kawecki S., Lazo J.S. Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN-01, a selective protein kinase C inhibitor. J Neurosurg. 84(6):1996;1024-1032.
26. Courage C., Budworth J., Gescher A. Comparison of ability of protein kinase C inhibitors to arrest cell growth and to alter cellular protein kinase C localisation. Br J Cancer. 71:1995;697-704.
27. Ikegami Y., Yano S., Nakao K. et al. Antitumour activity of the new selective protein kinase C inhibitor 4′-N-benzoyl staurosporine on murine and human tumour models. Arzneimittelforsch. 45:1995;1225-1230.
28. Utz I., Hofer S., Regenass U. et al. The protein kinase C inhibitor CGP 41251, a staurosporine derivative with antitumour activity, reverses multidrug resistance. Int J Cancer. 57:1994;104-110.
29. Beltran P.J., Fan D., Fidler I.J., O'Brian C.A. Chemosensitization of cancer cells by the staurosporine derivative CGP 41251 in association with decreased P-glycoprotein phosphorylation. Biochem Pharmacol. 53:1997;245-247.
30. Akinaga S., Nomura K., Gomi K., Okabe M. Enhancement of antitumour activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C. Cancer Chemother Pharmacol. 32:1993;183-189.
31. Budworth J., Davies R., Malkhandi J. et al. Comparison of staurosporine and four analogues: their effects on growth, rhodamine 123 retention and binding to P-glycoprotein in multidrug-resistant MCF-7/Adr cells. Br J Cancer. 73:1996;1063-1068.
32. Sedlak J., Hunakova L., Duraj J. et al. Effects of protein kinase C inhibitor, staurosporine derivative CGP 41 251, on cell cycle, DNA synthesis and drug uptake in neoplastic cell lines. Anti Cancer Drugs. 6:1995;70-76.
33. Sedlak J., Hunakova L., Sulikova M., Chorvath B. Protein kinase inhibitor-induced alterations of drug uptake, cell cycle and surface antigen expression in human multidrug-resistant (Pgp and MRP) promyelocytic leukaemia HL-60 cells. Leuk Res. 21:1997;449-458.
34. Courage C., Bradder S.M., Jones T. et al. Characterisation of novel human lung carcinoma cell lines selected for resistance to anti-neoplastic analogues of staurosporine. Int J Cancer. 73:1997;763-768.
35. Toledo M.M., Lydon N.B. Structures of staurosporine bound to CDK2 and cAPK-new tools for structure-based design of protein kinase inhibitors. Structure. 5:1997;1551-1556.
36. Mizuno K., Noda K., Ueda Y. et al. UCN-01, an anti-tumor drug, is a selective inhibitor of the conventional PKC subfamily. FEBS Lett. 359:1995;259-261.
37. Geiges D., Meyer T., Marte B. et al. Activation of protein kinase C subtypes alpha, gamma, delta, epsilon, zeta, and eta by tumor-promoting and nontumor-promoting agents. Biochem Pharmacol. 53:1997;865-875.
38. Takahashi Y., Saitoh Y., Yoshida M. et al. UCN-01 and UCN-02, new selective inhibitors of protein kinase C II purification physiochemical properties, structural determination and biological activities. J Antibiot. 42:1989;571-576.
39. Takahashi Y., Kobayashi E., Asano K. et al. UCN-01, a selective inhibitor of protein kinase C from streptomyces. J Antibiot. 40:1987;1782-1784.
40. Takahashi Y., Kobayashi E., Asano K. et al. UCN-01 and UCN-02, new selective inhibitors of protein kinase C. I Screening, producing organism and fermentation. J Antibiot. 42:1989;564-570.
41. Budworth J., Gescher A. Differential inhibition of cytosolic and membrane-derived protein kinase C activity by staurosporine and other kinase inhibitors. FEBS Lett. 362:1995;139-142.
42. Norbury C., Nurse P. Animal cell cycles and their controls. Ann Rev Biochem. 61:1992;441-470.
43. Weinberg R.A. The retinoblastoma protein and cell cycle control. Cell. 81:1995;323-330.
44. Courage C., Snowden R., Gescher A. Differential effects of staurosporine analogues on cell cycle, growth and viability in A549 cells. Br J Cancer. 74:1996;1199-1205.
45. Nishi K., Schnier J.B., Bradbury E.M. The accumulation of cyclin-dependent kinase inhibitor p27 kip1 is a primary response to staurosporine and independent of G1 cell cycle arrest. Exp Cell Res. 243:1998;222-231.
46. Kawakami K., Futami H., Takahara J., Yamaguchi K. UCN-01, 7-Hydroxyl-staurosporine, inhibits kinase activity of cyclin-dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line. Biochem Biophys Res Commun. 219:1996;778-783.
47. Akiyama T., Yoshida T., Tsujita T. et al. G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells. Cancer Res. 57:1997;1495-1501.
48. Wang Q., Fan S., Eastman A. et al. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted P53. J Natl Cancer Inst. 88:1996;956-965.
49. Bunch R.T., Eastman A. Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor. Clin Cancer Res. 2:1996;791-797.
50. Shao R.G., Shimizu T., Pommier Y. 7-Hydroxystaurosporine (UCN-01) induces apoptosis in human colon carcinoma and leukaemia cells independently of p53. Exp Cell Res. 234:1997;388-397.
51. Bunch R.T., Eastman A. 7-Hydroxystaurosporine (UCN-01) causes redistribution of proliferating cell nuclear antigen and abrogates cisplatin-induced S-phase arrest in Chinese hamster ovary cells. Cell Growth Differ. 8:1997;779-788.
52. Harkin S., Cohen G.R., Gescher A. Modulation of apoptosis in rat thymocytes by analogs of staurosporine: lack of direct association with inhibition of protein kinase C. Mol Pharmacol. 54:1998;663-670.
53. Wang Q., Worland P.J., Clark J.L. et al. Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2. Cell Growth Differ. 6:1995;927-936.
54. Hunakova L., Sulikova M., Duraj J. et al. Stimulation of 1-(beta-D-arabinosyl)cytosine (Ara-C)-induced apoptosis in multidrug resistant human promyelocytic leukemia cell lines with protein kinase C inhibitors. Neoplasma. 43:1996;291-295.
55. Wang S., Vrana J.A., Bartimole T.M. et al. Agents that down-regulate or inhibit protein kinase C circumvent resistance to 1-beta-D-arabinofuranosylcytosine-induced apoptosis in human leukemia cells that overexpress Bcl-2. Mol Pharmacol. 52:1997;1000-1009.
56. Han E.K., Begemann M., Sgambato A. et al. Increased expression of cyclin D1 in a murine mammary epithelial cell line induces p27kip1, inhibits growth, and enhances apoptosis. Cell Growth Differ. 7:1996;699-710.
57. Hill D.L., Tillery K.F., Rose L.M., Posey C.F. Disposition in mice of 7-hydroxystaurosporine, a protein kinase inhibitor with antitumor activity. Cancer Chemother Pharmacol. 35:1994;89-92.
58. 1-acid glycoprotein. Cancer Res. 58:1998;3248-3253.
59. McDonald A.C., Propper D., King D. et al. Phase I and pharmacokinetic study of CGP 41251, an inhibitor of protein kinase C. Proc Am Soc Clin Oncol. 16:1997;742.
60. Mehta A.B., Virchis A.E., Jones D.T. et al. Preliminary results of a phase 2 study on a protein kinase C inhibitor (CGP 41251) in low grade lymphoproliferative disorders. Blood. 90(Suppl. 1):1997;3646.
61. Gescher A. Towards selective pharmacological modulation of protein kinase C-opportunities for the design of novel chemotherapeutic agents? Br J Cancer. 66:1992;10-19.
62. Han Z.T., Zhu X.X., Yang R.Y. et al. Effect of intravenous infusions of 12-O-tetradecanoylphorbol-13-acetate (TPA) in patients with myelocytic leukemia: preliminary studies of therapeutic efficacy and toxicity. Proc Natl Acad Sci USA. 95:1998;5357-5361.